Tempus AI, Inc. (NASDAQ:TEM) Stock Has Consensus Price Target of $79.37

Shares of Tempus AI, Inc. (NASDAQ:TEM) have earned a consensus recommendation of “Hold” from the twenty-two ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $79.37.

A number of analysts recently weighed in on the stock. Weiss Ratings raised shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 13th. Robert W. Baird raised their target price on shares of Tempus AI from $85.00 to $92.00 and gave the company an “outperform” rating in a research report on Tuesday, November 3rd. Cantor Fitzgerald raised their target price on shares of Tempus AI from $80.00 to $92.00 and gave the company an “overweight” rating in a research report on Tuesday, November 3rd. Rothschild & Co Redburn began coverage on shares of Tempus AI in a report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price target for the company. Finally, BTIG Research upped their price target on shares of Tempus AI from $80.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, November 3rd.

Tempus AI Price Performance

Shares of TEM stock opened at $80.54 on Friday. Tempus AI has a twelve month low of $40.77 and a twelve month high of $89.09. The stock has a market capitalization of $14.69 billion, a price-to-earnings ratio of -75.98 and a beta of 3.61. The stock has a fifty day simple moving average of $72.08 and a two-hundred day simple moving average of $57.40. The company has a current ratio of 2.61, a quick ratio of 2.48 and a debt-to-equity ratio of 2.70.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. The business had revenue of $411.54 million for the quarter, compared to the consensus estimate of $409.39 million. Tempus AI had a negative return on equity of 47.00% and a negative net margin of 12.54%. The business’s revenue was up 23.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.46) EPS. On average, analysts predict that Tempus AI will post -1.20 EPS for the current fiscal year.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, CFO James Rogers sold 26,313 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the completion of the sale, the chief financial officer owned 106,024 shares in the company, valued at $6,361,440. This represents a 19.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 22,148 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $1,098,762.28. Following the sale, the executive vice president directly owned 146,067 shares in the company, valued at $7,246,383.87. This trade represents a 13.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 1,237,227 shares of company stock valued at $85,388,983. 24.26% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 23.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after purchasing an additional 821,490 shares in the last quarter. Amova Asset Management Americas Inc. grew its stake in Tempus AI by 23.4% in the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares during the last quarter. Pictet Asset Management Holding SA raised its holdings in Tempus AI by 2,965.7% in the third quarter. Pictet Asset Management Holding SA now owns 502,897 shares of the company’s stock worth $41,233,000 after purchasing an additional 486,493 shares in the last quarter. Eagle Health Investments LP bought a new position in Tempus AI in the first quarter worth about $11,588,000. Finally, Public Sector Pension Investment Board bought a new position in Tempus AI in the third quarter worth about $9,992,000. 24.22% of the stock is owned by institutional investors.

Tempus AI Company Profile

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.